Assessment of Stroke
Participants were continuously monitored for incident stroke, which were identified from medical records and confirmed by an experienced vascular neurologist. 8 
Statistical Analysis
We calculated hazard ratios and 95% confidence intervals with Cox proportional hazards models. We analyzed participants based on HADS-A score (categorically using 2 cut-offs: ≥8 versus <8 and ≥11 versus <11, and continuously per SD) and on Munich version of the Composite International Diagnostic Interview (at least 1 disorder [generalized anxiety disorder, panic disorder, agoraphobia, social phobia, or specific phobia] versus no disorder, and the separate subtypes of anxiety disorder versus no disorder).
Results
Baseline characteristics of the study samples are presented in Table 1 . Average (±SD) follow-up in the sample undergoing HADS-A was 12.5 (±5.3) years during which 332 strokes occurred: 204 ischemic and 30 hemorrhagic. Average follow-up in the sample undergoing Munich version of the Composite International Diagnostic Interview was 5.6 (±2.1) years during which 340 strokes occurred: 237 ischemic and 40 hemorrhagic.
Neither anxiety symptoms nor anxiety disorders were associated with the risk of stroke after complete follow-up (Table 2; Table I in the online-only Data Supplement): the multivariate adjusted hazard ratio was 1.02 (95% confidence interval, 0.74-1.43) for anxiety symptoms (HADS-A≥8 compared with HADS-A<8) and 0.95 (0.64-1.43) for any versus no anxiety disorder. The stricter dichotomization of HADS-A (≥11 versus <11) resulted in stronger effects although still not significant. We also did not observe any association for the separate subtypes of anxiety disorder or when we examined anxiety symptoms on a continuous scale (Table II in the online-only Data Supplement; Table 2 ).
Inspection of the survival curve ( Figure I in the onlineonly Data Supplement) pointed toward a possible short-term effect for anxiety symptoms. Indeed, an increased HADS was associated with an increased risk of stroke in the first 3 years of follow-up (hazard ratio, 2.55 [1.45-4 .46] for HADS-A≥8 
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compared with HADS-A<8; Table III in the online-only Data Supplement). After additional adjustment for depressive symptoms, the association remained similar.
Discussion
In this prospective population-based cohort study, we found no long-term association between anxiety and the risk of stroke. Two previous cohort studies assessed the association between anxiety and stroke: in one study, the risk of stroke increased with increasing anxiety symptom score, 4 whereas in the other study, psychological distress was associated with stroke but not with generalized anxiety disorder. 3 A reason for the differences may be the different scores to assess anxiety. Anxiety symptoms coincide with depressive symptoms and stress symptoms. Vice versa, depressive symptoms and stress symptoms have been related to stroke before. 9, 10 In our study, we detected only a short-term increased risk of stroke in people with anxiety symptoms, independent of depressive symptoms. This may be a true effect with possible mechanisms being activation of the hypothalamic-pituitary-adrenal axis and sympathetic nervous system or adverse health behaviors.
1 This is further supported by the finding that a stricter dichotomization of the anxiety symptom score resulted in stronger effects. Moreover, there may have been some nondifferential misclassification in our assessment of anxiety, which could have resulted in an underestimation of the true effect. In contrast, the lack of a long-term effect argues against a true effect. Moreover, we found no associations with anxiety disorders, for which any mechanism should have a similar effect. An alternative explanation may, thus, be reversed causality as suggested previously for mortality. 11 Given that patients with stroke have a high cardiovascular risk, they may experience a worsening health in the years preceding stroke and get anxious in response.
Strengths of our study are the population-based setting, the long follow-up period, the stringent stroke monitoring, and the limited loss of follow-up. A limitation is that due to lacking neuroimaging after stroke, 20% of all strokes remained of unspecified subtype. In addition, we did not perform a formal evaluation of the reliability of our anxiety assessments. Furthermore, we may have missed weak associations: assuming α=0.05, our study had a power of 0.77 to detect the hazard ratio of 1.43 that was found previously for high versus low anxiety (in our study HADS-A score, ≥8 versus <8). 4, 12 In conclusion, anxiety disorders were not associated with stroke in this general population study. Anxiety symptoms were only associated to stroke in the short term, which needs further exploration. 
Supplemental Methods
Setting and study population:
The Rotterdam Study is a prospective population-based cohort study, with repeat examination rounds every 3 to 4 years. 1 The original cohort (RS-I) started in 1990 and was expanded twice in 2000 (RS-II) and 2006 (RS-III). Currently, the study consists of 14,926 participants aged ≥45 years. 1 Anxiety symptoms were assessed once, in the 2 nd round of the RS-I subcohort (1993) (1994) (1995) . This round was attended by 6,315 participants. A random half of these participants (N=3,060) was invited to undergo the Hospital Anxiety and Depression Scale -Anxiety (HADS-A), of whom 2,975 were sufficiently screened on anxiety symptoms. We excluded participants without informed consent for retrieval of follow-up data (n=22), with prevalent stroke (n=84) or with prevalent (n=38) or missing data on dementia (n=206). Therefore, 2,625 participants were eligible for the analysis. Anxiety disorders were assessed in the 4 th round of the RS-I subcohort, the 2 nd round of the RS-II subcohort, and the 1 st round of the RS-III subcohort (2002) (2003) (2004) , using the Munich version of the Composite International Diagnostic Interview (M-CIDI). Of the 9,996 participants that attended these rounds, 9,974 underwent the interview. Of these, 9,426 participants had a valid anxiety assessment. After excluding participants without informed consent (n=62), with prevalent stroke (n=364), with prevalent (n=52) or missing data on dementia (n=280), or incomplete follow-up (n=6), 8,662 participants were eligible for this analysis. In total, 1,460 participants were overlapping across the sample that received the HADS-A and the sample that received the M-CIDI. The Rotterdam Study has been approved by the Medical Ethics Committee of the Erasmus MC and by the Ministry of Health, Welfare and Sport of the Netherlands, implementing the Wet Bevolkingsonderzoek: ERGO (Population Studies Act: Rotterdam Study). All participants provided written informed consent to participate in the study and to obtain information from their treating physicians.
Assessment of anxiety:
We used the HADS-A to measure anxiety symptoms. Participants filled in the questionnaire by themselves. The HADS-A is a subscale of the HADS 2 , a brief questionnaire that is used for the self-assessment of anxiety (HADS-A) and depressive symptoms (HADS-D). It measures anxiety including 7 items. The total score ranges from 0-21, and the HADS-A has an optimal balance between sensitivity and specificity for identifying anxiety disorder cases at a cutoff score of ≥8. 2 We also used a cutoff score of >11, which includes fewer false positives. The 1-year prevalence of anxiety disorders was assessed using a slightly adapted version of the M-CIDI.
according to the DSM-IV-TR criteria: generalized anxiety disorder, panic disorder, agoraphobia, social phobia, and specific phobia. 4 
Assessment of stroke:
Stroke was defined according to World Health Organization criteria. 6 After enrollment, participants were continuously monitored for incident stroke through automated linkage of the study database with medical records from general practitioners. Additional information was obtained from hospital records as described previously. 6 Strokes were classified as ischemic or hemorrhagic based on neuroimaging reports. Strokes were classified as unspecified if no neuroimaging was performed. 6 The follow-up was complete until January 1, 2012, for 93.1% of potential person-years.
Assessment of covariates:
We considered age, sex, systolic blood pressure, diastolic blood pressure, blood pressurelowering medication, total cholesterol, high-density lipoprotein cholesterol, lipid-lowering medication, smoking, diabetes mellitus type 2, body mass index, and myocardial infarction as potential confounders and their assessment has been described previously. 1, 7 Information about cholesterol, lipid-lowering medication, and diabetes mellitus was unavailable for the visit of the HADS cohort and was therefore obtained from one visit earlier. Depressive symptoms were obtained from the HADS Depression subscale (HADS-D). 2 
Statistical analysis:
We calculated hazard ratios (HRs) and 95% confidence intervals (CIs) with Cox proportional hazards models using IBM SPSS Statistics version 21. We analyzed participants based on HADS-A score (continuously per standard deviation (SD) and categorically using score ≥8 versus score <8 and score ≥11 versus score <11) and based on M-CIDI (at least one disorder [generalized anxiety disorder, panic disorder, agoraphobia, social phobia, or specific phobia] versus no disorder, and the separate subtypes of anxiety disorder versus no disorder). Participants were censored at date of stroke, date of death, last date of follow-up or January 1, 2012. Additionally, we constructed Kaplan-Meier curves to detect possible short-term effects. Covariates were missing up to a maximum of 9% and imputed based on the other covariates using multiple imputation with 5 imputation sets. Abbreviations: n = number of strokes, N = number of participants at risk, NA = not applicable, HR = hazard ratio. Adjusted for age, sex, systolic blood pressure, diastolic blood pressure, blood pressure-lowering medication, total cholesterol, highdensity lipoprotein cholesterol, lipid-lowering medication, diabetes mellitus, myocardial infarction, smoking, and body mass index.
